111 related articles for article (PubMed ID: 8155391)
1. Low-dose interleukin-2 subcutaneous immunotherapy in association with the pineal hormone melatonin as a first-line therapy in locally advanced or metastatic hepatocellular carcinoma.
Aldeghi R; Lissoni P; Barni S; Ardizzoia A; Tancini G; Piperno A; Pozzi M; Ricci G; Conti A; Maestroni GJ
Eur J Cancer; 1994; 30A(2):167-70. PubMed ID: 8155391
[TBL] [Abstract][Full Text] [Related]
2. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
Lissoni P; Barni S; Rovelli F; Brivio F; Ardizzoia A; Tancini G; Conti A; Maestroni GJ
Eur J Cancer; 1993; 29A(2):185-9. PubMed ID: 8422280
[TBL] [Abstract][Full Text] [Related]
3. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
Lissoni P; Tisi E; Barni S; Ardizzoia A; Rovelli F; Rescaldani R; Ballabio D; Benenti C; Angeli M; Tancini G
Br J Cancer; 1992 Jul; 66(1):155-8. PubMed ID: 1322155
[TBL] [Abstract][Full Text] [Related]
4. Neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin as a second-line treatment in metastatic colorectal carcinoma.
Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Paolorossi F; Brivio F; Perego M; Tancini G; Conti A; Maestroni G
Tumori; 1992 Dec; 78(6):383-7. PubMed ID: 1297233
[TBL] [Abstract][Full Text] [Related]
5. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R
Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
7. Neuroimmunotherapy of untreatable metastatic solid tumors with subcutaneous low-dose interleukin-2, melatonin and naltrexone: modulation of interleukin-2-induced antitumor immunity by blocking the opioid system.
Lissoni P; Malugani F; Malysheva O; Kozlov V; Laudon M; Conti A; Maestroni G
Neuro Endocrinol Lett; 2002 Aug; 23(4):341-4. PubMed ID: 12195238
[TBL] [Abstract][Full Text] [Related]
8. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
Lissoni P; Brivio F; Brivio O; Fumagalli L; Gramazio F; Rossi M; Emanuelli G; Alderi G; Lavorato F
J Biol Regul Homeost Agents; 1995; 9(1):31-3. PubMed ID: 8553906
[TBL] [Abstract][Full Text] [Related]
9. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
Lissoni P; Barni S; Ardizzoia A; Brivio F; Tancini G; Conti A; Maestroni GJ
J Biol Regul Homeost Agents; 1992; 6(4):132-6. PubMed ID: 1296454
[TBL] [Abstract][Full Text] [Related]
10. A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.
Lissoni P; Barni S; Fossati V; Ardizzoia A; Cazzaniga M; Tancini G; Frigerio F
Support Care Cancer; 1995 May; 3(3):194-7. PubMed ID: 7655780
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous therapy with low-dose interleukin-2 plus the neurohormone melatonin in metastatic gastric cancer patients with low performance status.
Lissoni P; Brivio F; Ardizzoia A; Tancini G; Barni S
Tumori; 1993 Dec; 79(6):401-4. PubMed ID: 8171739
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
13. Immunoendocrine therapy with low-dose subcutaneous interleukin-2 plus melatonin of locally advanced or metastatic endocrine tumors.
Lissoni P; Barni S; Tancini G; Mainini E; Piglia F; Maestroni GJ; Lewinski A
Oncology; 1995; 52(2):163-6. PubMed ID: 7854778
[TBL] [Abstract][Full Text] [Related]
14. A study of the mechanisms involved in the immunostimulatory action of the pineal hormone in cancer patients.
Lissoni P; Barni S; Tancini G; Rovelli F; Ardizzoia A; Conti A; Maestroni GJ
Oncology; 1993; 50(6):399-402. PubMed ID: 8233281
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.
Lissoni P; Barni S; Cazzaniga M; Ardizzoia A; Rovelli F; Brivio F; Tancini G
Oncology; 1994; 51(4):344-7. PubMed ID: 8208518
[TBL] [Abstract][Full Text] [Related]
16. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract.
Lissoni P; Barni S; Tancini G; Ardizzoia A; Rovelli F; Cazzaniga M; Brivio F; Piperno A; Aldeghi R; Fossati D
Br J Cancer; 1993 Jun; 67(6):1404-7. PubMed ID: 8512825
[TBL] [Abstract][Full Text] [Related]
18. A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates.
Barni S; Lissoni P; Cazzaniga M; Ardizzoia A; Meregalli S; Fossati V; Fumagalli L; Brivio F; Tancini G
Oncology; 1995; 52(3):243-5. PubMed ID: 7715908
[TBL] [Abstract][Full Text] [Related]
19. Pineal-opioid system interactions in the control of immunoinflammatory responses.
Lissoni P; Barni S; Tancini G; Fossati V; Frigerio F
Ann N Y Acad Sci; 1994 Nov; 741():191-6. PubMed ID: 7825805
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin.
Lissoni P; MandalĂ M; Brivio F
Eur Urol; 2000 Jul; 38(1):115-8. PubMed ID: 10859453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]